Valeritas Holdings, Inc. (OTCBB:CYGM) Files An 8-K Other Events
Item 8.01Other Events.

On April 26, 2018, Valeritas Holdings, Inc. (the “Company”) closed its previously announced public offering, in which it sold an aggregate of 13,700,000 shares of its common stock, $0.001 par value per share, at a public offering price of $1.75 per share before underwriting discounts and commissions to Oppenheimer & Co. Inc. (“Oppenheimer”), as representative for the several underwriters named in the Underwriting Agreement (as defined below), in accordance with and to the terms of an underwriting agreement, dated as of April 23, 2018 (the “Underwriting Agreement”), by and between the Company and Oppenheimer (the “Offering”). Total net proceeds to the Company from the Offering are expected to be approximately $21.5 million after deducting the underwriting discounts and commissions and estimated offering expenses payable by the Company. Oppenheimer acted as the sole book-running manager for the Offering, and National Securities Corporation, a wholly-owned subsidiary of National Holdings Corporation, acted as co-manager in connection with the Offering.

On April 24, 2018, the Company issued a press release announcing pricing of the Offering. A copy of the press release is attached as Exhibit 99.1 hereto.

Neither the disclosures on this Current Report on Form 8-K nor the attached press release shall constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements, all of which are subject to risks and uncertainties. Forward-looking statements can be identified by the use of words such as “expects,” “plans,” “will,” “projects,” “intends,” “estimates,” and other words of similar meaning. Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement. Readers should carefully consider any such statement and should understand that many factors could cause actual results to differ from these forward-looking statements. These factors may include inaccurate assumptions and a broad variety of other risks and uncertainties, including some that are known and some that are not. No forward-looking statement can be guaranteed, and actual future results may vary materially. Except as required by law, the Company does not assume any obligation to update any forward-looking statement.

Item 8.01Financial Statements and Exhibits.

(d) Exhibits.

EXHIBIT INDEX

Valeritas Holdings Inc. Exhibit
EX-99.1 2 exhibit99142718.htm EXHIBIT 99.1 Exhibit Valeritas Announces Pricing of $24 Million Public Offering of Common StockBRIDGEWATER,…
To view the full exhibit click here

About Valeritas Holdings, Inc. (OTCBB:CYGM)

Valeritas Holdings, Inc. is a commercial-stage medical technology company. The Company is focused on developing technologies for Type 2 diabetes. The Company’s product, the V-Go Wearable Insulin Delivery Device (V-Go), is an insulin delivery device that helps patients with Type 2 diabetes requiring insulin to maintain their target blood glucose goals. V-Go is a disposable insulin delivery device that a patient adheres to his or her skin every 24 hours. V-Go enables patients to closely mimic the body’s normal physiologic pattern of insulin delivery throughout the day and to manage their diabetes with insulin without the need to plan a daily routine around multiple daily injections. The Company has developed V-Go utilizing its h-Patch platform as a patient-focused solution to address insulin therapies. Its h-Patch platform facilitates the subcutaneous delivery of injectable medicines to patients across a range of therapeutic areas.